ÂÜÀòÂÒÂ×

Dr. Michael Walker has been a director and CEO of Verona Pharma since September 2006. He is an Emeritus Professor at the Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Canada and has founded and managed various biotech companies in Canada and the UK. His research interests are wide including many aspects of general pharmacology (from basic to clinical studies), marine toxins, and respiratory and cardiac pharmacology.

Dr. Walker was the founder of Rhythm Search Developments (RSD) Ltd., which company evolved into Nortran Pharmaceuticals Inc. and subsequently Cardiome Pharma Corp. (TSX: COM, NASDAQ: CRME) whose drug, RSD1235, for the acute termination of atrial fibrillation (a disorder of heart beating), is currently the subject of a New Drug Application filed with the US Food and Drug Administration.